Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

867 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Among authors: holt mv. Mol Cancer Ther. 2024 May 23. doi: 10.1158/1535-7163.MCT-23-0564. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38781103
Correction: Unravelling cell type-specific responses to Parkinson's Disease at single cell resolution.
Martirosyan A, Ansari R, Pestana F, Hebestreit K, Gasparyan H, Aleksanyan R, Hnatova S, Poovathingal S, Marneffe C, Thal DR, Kottick A, Hanson-Smith VJ, Guelfi S, Plumbly W, Belgard TG, Metzakopian E, Holt MG. Martirosyan A, et al. Among authors: holt mg. Mol Neurodegener. 2024 Mar 25;19(1):28. doi: 10.1186/s13024-024-00717-9. Mol Neurodegener. 2024. PMID: 38528600 Free PMC article. No abstract available.
Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data.
Lippenszky L, Mittendorf KF, Kiss Z, LeNoue-Newton ML, Napan-Molina P, Rahman P, Ye C, Laczi B, Csernai E, Jain NM, Holt ME, Maxwell CN, Ball M, Ma Y, Mitchell MB, Johnson DB, Smith DS, Park BH, Micheel CM, Fabbri D, Wolber J, Osterman TJ. Lippenszky L, et al. Among authors: holt me. JCO Clin Cancer Inform. 2024 Feb;8:e2300207. doi: 10.1200/CCI.23.00207. JCO Clin Cancer Inform. 2024. PMID: 38427922 Free PMC article.
Repositioning the Early Pathology of Type 1 Diabetes to the Extraislet Vasculature.
Costanzo A, Clarke D, Holt M, Sharma S, Nagy K, Tan X, Kain L, Abe B, Luce S, Boitard C, Wyseure T, Mosnier LO, Su AI, Grimes C, Finn MG, Savage PB, Gottschalk M, Pettus J, Teyton L. Costanzo A, et al. Among authors: holt m. J Immunol. 2024 Apr 1;212(7):1094-1104. doi: 10.4049/jimmunol.2300769. J Immunol. 2024. PMID: 38426888 Free PMC article.
867 results